A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.
about
Overactive bladder in the vulnerable elderlyAnticholinergic burden and cognitive function in a large German cohort of hospitalized geriatric patients.Brain penetration of the OAB drug trospium chloride is not increased in aged mice.Effect of anticholinergic use for the treatment of overactive bladder on cognitive function in postmenopausal womenTumor P-Glycoprotein Correlates with Efficacy of PF-3758309 in in vitro and in vivo Models of Colorectal CancerRationale for the use of anticholinergic agents in overactive bladder with regard to central nervous system and cardiovascular system side effects.Delirium following fesoterodine treatment for urgency incontinence in an 89-year old man.Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder.Evaluation of fesoterodine fumarate for the treatment of an overactive bladder.Emerging treatments for urinary incontinence.Selectivity of pharmacological tools: implications for use in cell physiology. A review in the theme: Cell signaling: proteins, pathways and mechanisms.Review of the efficacy and safety of fesoterodine for treating overactive bladder and urgency urinary incontinence in elderly patients.Treatment of Overactive Bladder in the Elderly Female: The Case for Trospium, Oxybutynin, Fesoterodine and Darifenacin.Differential effects of the enantiomers of tamsulosin and tolterodine on P-glycoprotein and cytochrome P450 3A4.Neurologic Complications of Commonly Used Drugs in the Hospital Setting.Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental studies.Synthesis and Biopharmaceutical Evaluation of Imatinib Analogues Featuring Unusual Structural Motifs.A pooled analysis of the efficacy of fesoterodine for the treatment of overactive bladder, and the relationship between safety, co-morbidity and polypharmacy in patients aged 65 years or older.Minimizing Drug Exposure in the CNS while Maintaining Good Oral AbsorptionDesign of Pyridopyrazine-1,6-dione γ-Secretase Modulators that Align Potency, MDR Efflux Ratio, and Metabolic Stability.Clinical pharmacology of functional disorders of the urogenital system.Drugs Interfering with Muscarinic Acetylcholine Receptors and Their Effects on Place Navigation.Imidafenacin has no influence on learning in nucleus basalis of Meynert-lesioned rats.Trifluoromethyl Oxetanes: Synthesis and Evaluation as a tert-Butyl Isostere.Making a Bad Diagnosis Worse? Suspect Drug Management of Urinary Incontinence in Persons with Dementia.A validated LC-MS/MS method for the determination of tolterodine and its metabolite in rat plasma and application to pharmacokinetic study.Evaluation of cognitive function in healthy older subjects treated with fesoterodine.Analytical Method Development and Validation of Solifenacin in Pharmaceutical Dosage Forms by RP-HPLCBioanalytical method for quantification of Solifenacin in rat plasma by LC-MS/MS and its application to pharmacokinetic study
P2860
Q34351806-1BE4C802-3723-4FDC-9488-4E8A84641BEEQ36277027-34B5374C-4023-4FB1-8F7D-527B6EEEAA44Q36568768-E6200EB3-B039-412E-8526-6E4251E12018Q36611322-42EDDAEC-1FB6-4869-9B4D-CCF0242A843BQ36708157-92823F40-E901-4828-AAA3-9C23C90E20FEQ37399563-5CBF29CB-7780-434D-AB37-913857ABA90BQ37666189-FDEF8670-D811-465E-AD46-B99B9F06AF2DQ37990531-FA8FAA4E-671C-498C-AA12-779A555779F5Q38160883-36F6C5E6-5EC3-43A7-89F4-8FCD58A5B2E7Q38195632-3A51AE48-8378-41F6-BA47-B3B57F1EF8EEQ38336214-46FA085F-12AC-4942-976A-B2D1FDF5CC01Q38352217-019E2EB0-F692-44F5-9AE3-5D300089BF30Q38590670-1D13D0EF-2B79-497B-AFF2-49E93ECCBE1AQ38743428-EF0D4488-8DF0-4F5D-AEC3-F0EFE4F5C7B1Q38746169-B26EA4EB-563B-43CD-B875-AA5B341DD700Q38765381-D9826C75-B1D0-48DA-92F6-0FF9978AA01BQ38818275-B433EA46-5E79-4CF0-A08B-E6720437AA2DQ39037375-A3C377AB-A350-4F66-8470-6061B0CBCAF8Q39733589-D24C7EC0-5E4E-426B-B601-E2BCBDED54ECQ40753596-95EFD89B-02D6-42E3-885C-15FEBBF158BEQ42876778-DEB7BDEE-92FC-4130-915E-0B3CA50CDFCAQ44073064-0D4A7B82-00E1-4A66-9626-2FDE1DC57C65Q45408584-7BB59B2A-43A4-43AC-A9FC-C37C087936DCQ47942169-65D0EC9A-C2EF-401D-B76F-5B4A997E79B6Q48028110-B9CA1DF5-1843-4B4C-AB40-9D0B179E785FQ50196650-9CAB8CFD-057C-40A8-9A2B-89B61C40843EQ50753347-E6DF781F-D373-4738-84C2-E65D4772B918Q59047146-2C892EB9-0B30-4C8A-9833-F6349BBBA37DQ59321671-7F1B2ADB-83D8-45BD-8A5D-50C229D0F66A
P2860
A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A comprehensive non-clinical e ...... eatment of overactive bladder.
@ast
A comprehensive non-clinical e ...... eatment of overactive bladder.
@en
type
label
A comprehensive non-clinical e ...... eatment of overactive bladder.
@ast
A comprehensive non-clinical e ...... eatment of overactive bladder.
@en
prefLabel
A comprehensive non-clinical e ...... eatment of overactive bladder.
@ast
A comprehensive non-clinical e ...... eatment of overactive bladder.
@en
P2093
P2860
P1476
A comprehensive non-clinical e ...... eatment of overactive bladder.
@en
P2093
Bimal Malhotra
Ernesto Callegari
Gary G Kay
Jennifer L LaPerle
Katherine S Fenner
Martin C Michel
Peter J Bungay
Rob Webster
Sarah Kempshall
P2860
P304
P356
10.1111/J.1365-2125.2011.03961.X
P407
P577
2011-08-01T00:00:00Z